- Home
- CNF vs SBFM Comparison
CNF vs SBFM Comparison
Compare CNF & SBFM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CNF
- SBFM
- Stock Information
- Founded
- CNF 1999
- SBFM 2006
- Country
- CNF China
- SBFM United States
- Employees
- CNF N/A
- SBFM N/A
- Industry
- CNF Finance: Consumer Services
- SBFM Biotechnology: Pharmaceutical Preparations
- Sector
- CNF Finance
- SBFM Health Care
- Exchange
- CNF Nasdaq
- SBFM Nasdaq
- Market Cap
- CNF 35.7M
- SBFM 6.7M
- IPO Year
- CNF 2018
- SBFM N/A
- Fundamental
- Price
- CNF $0.76
- SBFM $1.56
- Analyst Decision
- CNF
- SBFM Strong Buy
- Analyst Count
- CNF 0
- SBFM 1
- Target Price
- CNF N/A
- SBFM $15.00
- AVG Volume (30 Days)
- CNF 175.7K
- SBFM 189.5K
- Earning Date
- CNF 08-27-2025
- SBFM 08-15-2025
- Dividend Yield
- CNF N/A
- SBFM N/A
- EPS Growth
- CNF N/A
- SBFM N/A
- EPS
- CNF 0.08
- SBFM N/A
- Revenue
- CNF $85,661,735.00
- SBFM $36,234,578.00
- Revenue This Year
- CNF $252.34
- SBFM $32.20
- Revenue Next Year
- CNF N/A
- SBFM $32.74
- P/E Ratio
- CNF $10.47
- SBFM N/A
- Revenue Growth
- CNF N/A
- SBFM 35.51
- 52 Week Low
- CNF $0.37
- SBFM $1.17
- 52 Week High
- CNF $2.84
- SBFM $6.99
- Technical
- Relative Strength Index (RSI)
- CNF 61.85
- SBFM 52.23
- Support Level
- CNF $0.72
- SBFM $1.42
- Resistance Level
- CNF $0.81
- SBFM $1.56
- Average True Range (ATR)
- CNF 0.08
- SBFM 0.10
- MACD
- CNF 0.00
- SBFM 0.00
- Stochastic Oscillator
- CNF 80.60
- SBFM 39.39
About CNF CNFinance Holdings Limited each representing twenty (20)
CNFinance Holdings Ltd is an equity loan service provider. It focuses on the development of small and micro-enterprises. It generates revenue in the form of interest and financing service fees on loans and interest on deposits with banks. Its primary target borrower segment is MSE owners who own real properties in Tier 1 and Tier 2 cities in China. Geographically, it has an operation in PRC.
About SBFM Sunshine Biopharma Inc.
Sunshine Biopharma Inc is a pharmaceutical company offering and researching life-saving medicines in a wide variety of therapeutic areas, including oncology and antivirals. Through its subsidiaries, the company has various generic prescription drugs on the market in Canada and is also involved in developing and selling OTC supplements. In addition, the company is conducting a proprietary drug development program, which is comprised of K1.1 mRNA targeted for liver cancer and SBFM-PL4, PLpro protease inhibitor for SARS Coronavirus infections.